GEM 91 genetic antisense compound targeted to products of the HIV-1 gag gene data

HYBN unblinded results of the three highest dose levels of its Phase Ib/II trial. The study tested decreases

Read the full 184 word article

How to gain access

Continue reading with a
two-week free trial.